secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117204
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics to reverse-merge with Journey Therapeutics, issuing 99% equity
--------------------------------------------------------------------------------

- Entero (ENTO) signs binding term sheet to acquire all Journey equity; Journey holders get 99% of combined company.
- Post-close, Journey CEO Henry Ji to become CEO and Chairman of the combined company.
- Conditions include $5M equity financing, S-4 effectiveness, Nasdaq listing, and ENTO stockholder approval.
- Combined entity will focus on Journey's NIC platform for oncology and Entero's GI pipeline (latiglutenase, adrulipase, capeserod).
- NIC platform licensed from Mayo Clinic; early Phase 1 data in ovarian/endometrial cancer and non-Hodgkin's lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924117204/0001104659-24-117204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924117204/tm2428268d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer